All articles by GlobalData Healthcare

  1. Late-stage PsA pipeline agents must prove their worth

    Despite the plethora of therapies currently available to patients with psoriatic arthritis (PsA), there is still room for improvement within…
    Read More…

    6 Feb
  2. Black US men have higher risk of breast cancer than white men

    Breast cancer is a malignant tumour that originates in the breast tissue. Most breast cancers are invasive tumours that have…
    Read More…

    6 Feb
  3. Different therapeutic regimens continue to show promise in multiple myeloma

    A number of therapeutic approaches are being evaluated for the treatment of multiple myeloma with very promising assets in the…
    Read More…

    6 Feb
  4. The rise of biosimilars in the US: will they make their mark in 2020?

    Expectations for biosimilars are high in 2020 and the drug class will finally begin to make its mark in the…
    Read More…

    5 Feb
  5. President Trump pushes for bipartisan legislation to lower drug prices

    In Trump’s State of the Union address on Tuesday, 4 February, he called for further bipartisan legislation to lower drug…
    Read More…

    5 Feb
  6. Identifying patient groups most severely affected by the coronavirus in China

    This week, Chen and colleagues published a follow-up report of the clinical characteristics of 99 patients with PCR-confirmed novel coronavirus…
    Read More…

    4 Feb
  7. Dermatophytic onychomycosis therapies drive market growth

    Onychomycosis is a fungal infection of the nail caused by dermatophytes, nondermatophyte moulds (NDMs), or yeast. It is the most…
    Read More…

    4 Feb
  8. Caution required in interpreting the infectiousness of coronavirus

    One of the most frequently asked questions during the novel 2019 coronavirus (2019-nCoV) outbreak, centered in Wuhan, China, is how…
    Read More…

    4 Feb
  9. Breast cancer: checkpoint inhibitors and antibody drug conjugates

    The treatment of human epidermal growth factor receptor 2-negative (HER2-) breast cancer, which encompasses the hormone receptor-positive (HR+) and triple-negative…
    Read More…

    3 Feb
  10. Nolasiban failure calls for development in female infertility sector

    In November 2019, ObsEva announced that nolasiban, its oral oxytocin receptor antagonist for patients undergoing in vitro fertilisation (IVF), failed…
    Read More…

    3 Feb
Close
Close
Close

Go Top